Zymo Research Granted CE IVD Mark for Sample Collection Devices
Safe and reliable sample preservation at ambient temperature for IVD applications
Zymo Research was granted the CE IVD mark for its DNA/RNA Shield™ reagent and collection devices.
IRVINE, Calif., (Sept. 25, 2020) — Zymo Research announced that three of its DNA/RNA Shield™ collection devices: 1) DNA/RNA Shield™ collection tube w/ swab, 2) DNA/RNA Shield™ Saliva/Sputum Collection Kit, and 3) DNA/RNA Shield™ Fecal Collection Tube are now CE IVD marked for in vitro diagnostic (IVD) applications.
The DNA/RNA Shield™ product line includes sample collection, preservation, and transportation devices for medical specimens used in research and are now available for in vitro diagnostics (e.g., COVID-19 testing). To receive the CE IVD mark, scientists at Zymo Research collected extensive performance data on sample (pathogen) inactivation and nucleic acid preservation. The results confirmed an unprecedented stabilization of the samples (weeks/months) and DNA (many years) when the samples were stored at ambient temperature. Since DNA/RNA Shield™ immediately inactivates pathogens, including SARS-CoV-2, the virus that causes COVID-19, sample transportation is much safer for laboratory professionals and frontline workers.
“We are standardizing sample collection in clinical and research settings,” said Dr. Stanislav Forman of Zymo Research Corp. “This technology provides a level of safety for first responders and service providers alike; while pathogens are inactivated, the nucleic acid signatures are maintained. The CE IVD mark allows us to support many more clinical labs and organizations globally, including those performing COVID-19 testing during the current pandemic.”
The CE IVD mark comes at a critical time, as many labs and organizations need sample collection devices to support COVID-19 testing workflows. Zymo Research already supports large-scale COVID-19 global testing efforts with its DNA/RNA Shield™ product, including the Corona Testing Centre at the Stuttgart Airport. The test center is operated by CeGaT GmbH, a provider of genetic diagnostics and NGS services, based in Tübingen, Germany. For the test, the DNA/RNA Shield™ collection tube w/swab is being used to collect nasopharyngeal samples from airport passengers, who are screened for SARS-CoV-2 viral RNA using a real-time polymerase chain reaction (RT-PCR) test. Test results are available the next day as part of the state’s efforts to contain the spread of COVID-19.
“We rely on Zymo Research sample collection tubes for acute SARS-CoV-2 diagnostics,” said Dr. med. Dr. rer. nat. Saskia Biskup, CEO Praxis für Humangenetik Tübingen & CeGaT GmbH. “We value the inactivating capabilities of the CE IVD-certified DNA/RNA Shield™ solution, which allows us safer sample handling and results in higher throughput in our lab.”
For more information about DNA/RNA Shield™ and collection devices, visit Zymo Research’s website or contact them via email at covid19requests@zymoresearch.com.
About Zymo Research Corp.
Zymo Research is a privately owned company that has been serving the scientific and diagnostics community with state-of-the-art molecular biology tools since 1994. “The Beauty of Science is to Make Things Simple” is their motto, which is reflected in all of their products, from epigenetics to DNA/RNA purification technologies. Historically recognized as the leader in epigenetics, Zymo Research is breaking boundaries with novel solutions for sample collection, microbiomic measurements, diagnostic devices, and NGS technologies that are high quality and simple to use. Follow Zymo Research on Facebook, LinkedIn, Twitter, and Instagram.
Media Contacts:
Marketing Department
Zymo Research Corp.
949.679.1190
marketing@zymoresearch.com
Sheila T. Brann, Media Relations
KIWI Communications, Inc.
714.979.3464
sbrann@kiwi-comm.com